CCM
ALXN

Copernicus Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Copernicus Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-85,000
Closed -$9.54M – 22
2020
Q2 		$9.54M Buy
+85,000
New +$9.02M 10.46% 3
2018
Q2 		– Sell
-50,000
Closed -$5.57M – 24
2018
Q1 		$5.57M Buy
+50,000
New +$5.98M 4.44% 12

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Copernicus Capital Management's ALXN Position: Q3 2020 in Review

Copernicus Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 85,000 shares — an estimated $9.54M sold.

Copernicus Capital Management first reported a position in ALXN in Q1 2018 and held it in 2 quarters. The position peaked at $9.54M in Q2 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Copernicus Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Copernicus Capital Management sold 85,000 Alexion Pharmaceuticals shares in Q3 2020, an estimated $9.54M.
  • Copernicus Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Copernicus Capital Management's Alexion Pharmaceuticals position peaked at $9.54M in Q2 2020.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Copernicus Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.